| Age, years mean (SD) | 66.1 (10.0) | 62.7 (9.5) | 67.3 (9.9) |
| Gender, female, n (%) | 118 (74) | 199 (82) | 15 (65) |
| Disease duration, median (IQR) years | 8 (3, 18) | 12 (6, 18) | 14 (5, 31) |
| DAS28, mean (SD) | 6.4 (10.7) | 7.0 (6.1) | 6.5 (1.0) |
| HAQ, mean (SD) | 1.7 (0.7) | 2.2 (0.5) | 2.1 (0.3) |
| Smoke current, n (%) | 32 (20) | 48 (20) | 4 (17) |
| Median time prior malignancy-registration, (IQR) years | 7.9 (3.0, 13.3) | 11.5 (5.8, 17.6) | 5.4 (3.0, 9.2) |
| Prior malignancy >10 years, n (%) | 59 (37.1) | 138 (56.8) | 4 (17.4) |
| IM, n | 40 | 38 | 2 |
| Follow-up, pyears | 855 | 1,591 | 81 |
| Median follow-up (years, IQR) | 6.6 (4.4, 7.8) | 6.9 (3.5, 8.8) | 3.9 (3.3, 4.6) |
| Crude rate/1000 pyrs (95% CI) | 47 (33, 64) | 24 (17, 32) | 25 (3, 89) |
| Unadjusted HR | Ref | 0.53 (0.34, 0.82) | 0.48 (0.12, 1.99) |
| Age & gender adjusted HR | Ref | 0.55 (0.35, 0.87) | 0.47 (0.11, 1.94) |